Pharmacy Times July 15, 2024
Mike Hennessy Jr, President and CEO

The 2024 American Society. ofClinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, highlighted significant advancements across various oncology disciplines.

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, highlighted significant advancements across various oncology disciplines. In the cover feature on page 10, Douglas Braun, PharmD, RPh, CSP, CPh, Pharmacy Practice in Focus: Oncology associate editor and editorial advisory board member, discusses some of the key findings presented at the meeting. Findings highlighted include the efficacy of lorlatinib (Lorbrena; Pfizer Inc) in ALK-positive non–small cell lung cancer (NSCLC), osimertinib (Tagrisso; AstraZeneca) in EGFR-mutated NSCLC post chemoradiotherapy, and amivantamab (Rybrevant; Janssen Biotech, Inc) noninferiority in EGFR-mutated NSCLC. Braun also highlighted advances in chimeric antigen receptor (CAR) T-cell therapy...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Conferences / Podcast, Physician, Provider, Trends
Related Articles:
Achieving Value-Based Care Through the Payvider Model
208 million Americans are classified as obese or overweight, according to new study on 132 data sources
Epic's new interoperability push, explained
How 3 Health Systems Are Scaling Hybrid & Home-Based Models
CMS finalizes new kidney transplant model: 10 things to know

Share This Article